Agilent continued its foray into diagnostics and scientific research equipment with the planned acquisition of Seahorse Bio for $235 million in cash. The deal is expected to close by Nov. 1.
Qualcomm Life is reaching further into healthcare and the hospital with its purchase of Capsule Technologie, thereby extending its existing focus on at-home healthcare products.
It's official: Mylan has taken its Perrigo buyout offer to the Irish company's shareholders. But plenty of industry-watchers are still opposed to the idea.
Infection prevention and control player Cantel Medical will purchase U.K. startup Medical Innovations Group for $79.5 million in cash. The acquisition adds a recently launched endoscope storage system as well as single-use endoscopy consumables, mobile cart systems and patient transport products.
After some serious pushback from Baxalta, Shire is weighing options when it comes to sweetening its $30.6 billion bid for the company. But it's not even sure how to go about doing it.
Infraredx will be acquired by its Japanese partner and investor Nipro. The pair had an exclusive 5-year distribution deal in Japan for the company to sell the startup's cardiac imaging system. Nipro has already gained Japanese approval for the NIRS-IVUS True Vessel Characterization Imaging System from Infraredx to find cholesterol-rich, lipid core coronary plaques that are thought to precipitate heart attack.
ZS Pharma, awaiting FDA approval for a kidney drug, saw its share value soar about 30% after Actelion confirmed that it's discussing a multibillion-dollar buyout with the company.
Horizon Pharma has officially begun mailing solicitation materials to shareholders of unwilling M&A target Depomed, including a letter related to its efforts to call the two special meetings it'll need if it wants to seal its deal.
All eyes are on Perrigo's investors, who will have to decide whether to accept Mylan's offer when the wannabe acquirer takes it to them next Monday. And Israeli businessman Mori Arkin, for one, plans to deliver a resounding "no."
When Gilead laid out the terms for raising $10 billion yesterday, on top of the blockbuster money it earns on HIV and its hepatitis C drugs acquired in its buyout of Pharmasset, the move immediately stirred fresh buzz about what Gilead was going to buy next, and for how much.